schemes targeted therapies for kidney cancerTargeted therapy - one of the latest developments in the treatment of cancer. It prevents its development on a molecular level. Targeted drugs disrupt the blood supply to the cancer cells and counteract their reproduction. They block commands that indicate abnormal cells on the growth.

Unlike standard chemotherapy, which affects all body cells, Targeted affects only malignant. Its mission - to prevent the specific molecules involved in tumor growth to inhibit the development and spread of the disease. Therefore, this treatment causes fewer side effects.

Kidneys abundant number of blood vessels, which contributes to the growth of tumor cells. For this reason, kidney cancer targeted therapy effective, offering angiogenic drugs. They affect the blood vessels that lead to cancer.

Treatment of kidney cancer in Israel is personalized and includes the most advanced treatment with the fewest possible side effects - laparoscopic and robotic surgery, cryotherapy, and radiofrequency ablation targeted therapy.

Our company, a medical service «Tlv.Hospital», offers the organization of treatment of this disease in Israel - from the best doctors in the shortest possible time, in the most comfortable conditions. Benefits of targeted therapies for kidney cancer in Israel professionalism of doctors, high-quality medicines, genetic diagnostics.

Indications and Treatment Planning

Targeted drugs are recommended:

  • with unresectable primary tumor;
  • in metastatic renal cell carcinoma;
  • in clinical trials to prevent recurrence of the disease after surgery.

Treatment involves the use of one or more drugs chosen for each patient treatment plan. In order to determine the most effective option is used risk stratification system, genetic testing is used. Health, especially the particular case of the disease affect the choice. During the consultation with a doctor in Israel, the patient has an opportunity to ask questions (sample list):

  1. whether the results will bring in a particular case targeted therapy, whether the aid will?
  2. What medications are available?
  3. Why targeted therapy was offered to me?
  4. What is the goal of treatment?
  5. Is there any other choice?
  6. What are the short and long term side effects?
  7. What measures can be taken to reduce the effect of unwanted side effects or prevent them?
  8. How long it will last treatment?

Drugs targeted first-line therapy for kidney cancer

Basically, these types of drugs are used to reduce or control the disease in disseminated malignancy. According to studies and reviews targeted therapy of renal cancer stops or slows the progression of the disease for several months, and sometimes - years.

Usually they take drugs until they are able to control the disease. The patient meets the doctor every 4-6 weeks, also losing blood tests. Once the scan is performed in three months, to find out whether the treatment effectively.

Consider the scheme targeted therapies for kidney cancer. Sunitinib (Sutent) is mainly recommended in the presence of the first secondary foci. Another common medication - pazopanib (Pazopanib). These drugs inhibit the growth signals in malignant cells and are called inhibitors of tyrosine kinase. Also, in some cases, prescribe sorafenib (Nexavar).

Sunitinib (Sunitinib)

Sunitinib has another name - Sutent. Its use 3 or 4 stages of disease. It is taken in capsules daily for 4 weeks followed by an interval of 2 weeks.

This drug belongs to the group of tyrosine kinase inhibitors. It blocks intracellular proteins called tyrosine kinases in tumor cells, which give signals to grow and divide, the cell associated with the nucleus and cellular structures. In addition, Sutent inhibits blood supply, depriving cells of abnormal supply of nutrients and oxygen.

Possible unwanted effects of administration include fatigue, increased risk of infection due to the low level of white blood cells, anemia, changes in taste, diarrhea, skin rash and itching, palmoplantar keratoderma, hypertension. Sunitinib may degrade the performance of the thyroid gland, for this reason, the patient regularly donates blood tests to check this.

Pazopanib (Pazopanib)

Pazopanib - cancer growth inhibitor, a doctor can recommend a drug as a primary treatment in advanced malignancy, and after application as secondary interferon or interleukin-2. It is available in tablets, it is taken every day. Potential adverse effects of the reception include: diarrhea, palmar-plantar keratoderma, rash and itching of the skin, fatigue, nausea.

Drugs targeted therapies for kidney cancer second-line

If treatment stops working and the cancer begins to grow again, the doctor prescribes a second line therapy. Appointed may be one of the above mentioned drugs. Or, the doctor will suggest bevacizumab (Avastin) intravenously with interferon. Other medications - Temsirolimus (Torisel) and everolimus (Afinitor). They block the growth signals, and called MTOR blockers (MTOR - a protein that controls the growth, division and cell metabolism).

Avastin in kidney cancer targeted therapy, and interferon

Bevacizumab (Avastin) - monoclonal antibody prevents the development of blood vessels in a tumor. The drug is administered intravenously every two weeks, interferon - three times a week by injection.

Most often observed when receiving interferon flu-like symptoms for a week - two. Reception paracetamol half hour before the injection may help - prevent or reduce them. Among the other adverse events noted bleeding from the nose, constipation - diarrhea, depression, nausea, hypertension.

Temsirolimus (Torisel)

Temsirolimus given intravenously once a week. It blocks signals in the growth of malignant cells, refers to preparations of MTOR inhibitors. It recommended for advanced malignancy as a secondary target therapy for kidney cancer. Adverse effects of therapy include: rash, itching and redness of the skin, nausea, loss of appetite, diarrhea, inflammation of the mouth; low levels of blood cells.

Everolimus (Afinitor)

Everolimus is available in tablets, taken once a day. As temsirolimus, Afinitor - it MTOR inhibitor, blocking the growth signals to cancer cells. Doctors use it as a second-line targeted therapy of kidney cancer metastases, when there is no response to Sutent and Sorafenib.

Possible undesired therapy include low resistance to infection, fatigue and shortness of breath due to insufficient levels of erythrocytes, elevated blood sugar and cholesterol, inflammation in the oral cavity; rash, itching, and dryness of the skin; nausea.

Sorafenib (Nexavar)

It is taken daily, orally. It works in both directions of targeted therapy for kidney cancer, it blocks the signals of growth and agiogeneza process in malignant tumors. Is used in the presence of secondary foci of kidney cancer when the drugs are not effective biologic therapy, the patient has an intolerance to Sutent.

Potential adverse events noted: diarrhea, excessive fatigue, palmar-plantar eritrodizesteziyu, nausea, hair thinning.

Reduced risk of recurrence

To date, no therapies that reduce the likelihood of recurrence of kidney cancer after surgery. But it carried a large amount of research in the world in which we study targeted therapies. new drugs of this type of treatment is also being developed.

General potential adverse effects of targeted therapies for kidney cancer

Each of the drug - its side effects. Most people, taking them to experience fatigue. Depending on how the medication side effects include diarrhea, skin rashes, pain in arms and legs. The doctor discusses with the patient in detail the issue and advises how to deal with them better.

Online video consultations with leading Israeli experts: about the benefits of online video consultation.